Low Dose Naltrexone is being developed as IRT-103/Lodonal via Immune Therapeutics, Inc.’s wholly owned subsidiary Cytocom, Inc. Development of IRT-103/Lodonal for Pediatric and Adult Crohn’s is currently in R&D to reach a Phase III US Trial. More information can be found at www.cytocom.com

Press Releases Regarding Cytocom, Inc.